The Priority Review

Tag

Pimjetmi

2 stories

Stories

  1. Approvals

    Abbisko's PIMJETMI receives U.S. FDA approval for TGCT

    The U.S. FDA approved PIMJETMI as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The approval follows earlier approvals in China, Canada and Switzerland and is based on the Phase III MANEUVER study showing a 56% objective response rate versus 3% for placebo.

  2. Approvals

    FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor

    On November 10, 2026, the FDA approved pimicotinib (Pimjetmi, EMD Serono, Inc.) for adults with symptomatic TGCT for whom surgical resection may cause worsening functional limitation or severe morbidity. The approval follows a double-blind, randomized, placebo-controlled MANEUVER trial that evaluated pimicotinib 50 mg once daily.